Explore our recent stories to see what drives us
Grünenthal strengthens QUTENZA brand and seeks further label expansion in the US
“Many patients still do not achieve satisfactory treatment outcomes. Qutenza can offer a meaningful treatment option for this debilitating disease.”
Post-surgical neuropathic pain (PSNP) is a debilitating complication of surgery that affects approximately 13 percent of all patients who undergo surgery1 – it’s characterised by burning, stabbing or shooting neuropathic pain. Commonly used oral, systemically acting medicines often provide unsatisfactory results or are accompanied by considerable side effects. QUTENZA, delivering prescription strength capsaicin directly to the skin, may offer a meaningful non-systemic and non-opioid treatment option.
Grünenthal acquired the exclusive commercial rights for QUTENZA in Europe, the Middle East and Africa in December 2016 and became the sole owner of the product in November 2018. In July 2020, Grünenthal and Averitas Pharma significantly expanded the reach of QUTENZA in the US by expanding the label to include the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. This complication of diabetes affected more than 5 million Americans in 20202, and the number of affected patients is expected to double by 20303.
Classifying surgeries were factored against their respective time-bound frequency of PSNP to yield the prevalence based on:
- Carroll, I. R., Hah, J. M., Barelka, P. L., Wang, C. K. M., Wang, B. M., Gillespie, M. J., … Mackey, S. C. (2015). Pain Duration and Resolution following Surgery: An Inception Cohort Study. Pain Medicine, 16(12), 2386–2396. doi:10.1111/pme.12842.
- Shipton, E. (2008). POST-SURGICAL NEUROPATHIC PAIN. ANZ Journal of Surgery, 78(7), 548–555. doi:10.1111/j.1445-2197.2008.04569.x
- Borsook, D., Kussman, B. D., George, E., Becerra, L. R., & Burke, D. W. (2013). Surgically Induced Neuropathic Pain. Annals of Surgery, 257(3), 403–412. doi:10.1097/sla.0b013e3182701a7b.
LTP 2020-2030: Addressable populations by condition (PDPN, PSNP, PHN, CINP). Company data on file. April 30, 2020.
Gore, M., Brandenburg, N. A., Dukes, E., Hoffman, D. L., Tai, K.-S., & Stacey, B. (2005). Pain Severity in Diabetic Peripheral Neuropathy is Associated with Patient Functioning, Symptom Levels of Anxiety and Depression, and Sleep. Journal of Pain and Symptom Management, 30(4), 374-385. doi:10.1016/j.jpainsymman.2005.04.009